FDA-Approved Ovarian Cancer Treatments
FDA-APPROVED OVARIAN CANCER TREATMENTS
Generic Brand Strength Form Usual Dose
Alkylating agent
carboplatin 10mg/
 
mL
soln for IV infusion Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1 every 4wks for 6 cycles
Recurrent ovarian cancer: 360mg/m² on Day 1 every 4wks
cisplatin 1mg/mL soln for IV infusion after dilution 75–100mg/m² IV per cycle once every 3–4wks on Day 1
50mg/vial pwd for IV infusion after reconstitution and dilution
cyclophos
phamide
25mg, 50mg tabs 1–5mg/kg/day
500mg, 1g, 2g pwd for inj after reconsti
tution
40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan 2mg scored tabs 0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa 15mg pwd for IV, intravesical, or intracavitary admini
stration after reconsti
tution
0.3–0.4mg/kg IV once every 1–4wks
Antibiotics (cytotoxic)
doxorubicin 10mg, 20mg, 50mg pwd for IV inj after reconsti
tution
Monotherapy: 60–75mg/m² every 21 days
Combination therapy: 40–60mg/m² every 21 to 28 days
2mg/mL soln for IV inj
doxorubicin (liposomal) Doxil 2mg/mL dispersion for IV infusion after dilution 50mg/m² once every 4wks; continue for ≥4 cycles as tolerated. Initial rate: 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur.
Antimetabolite
gemcitabine 200mg, 1g, 2g pwd for IV infusion after reconsti
tution
1000mg/m² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine
Infugem 1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL soln for IV infusion
Antimicrotubule agents
paclitaxel 6mg/mL soln for IV infusion after dilution Previously untreated ovarian cancer: 175mg/m² IV over 3hrs + cisplatin; or 135mg/m² IV over 24hrs + cisplatin; repeat every 3wks
Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3hrs every 3wks
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR
niraparib Zejula 100mg caps First-line maintenance of advanced ovarian cancer: start within 12wks after most recent platinum-containing regimen; (patients <77kg or with platelets <150000/μL): 200mg once daily; (patients ≥77kg and platelets ≥150000/μL): 300mg once daily. Maintenance of recurrent ovarian cancer: start within 8wks after most recent platinum-containing regimen; 300mg once daily. All: continue until disease progression or unacceptable toxicity.
olaparib Lynparza 100mg, 150mg tabs 300mg twice daily.
First-line maintenance of BRCA-mutated or HRD-positive advanced ovarian: continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment.
Maintenance of recurrent ovarian or germline BRCA-mutated advanced ovarian: continue until disease progression or unacceptable toxicity. In combination with bevacizumab: give bevacizumab (15mg/kg every 3wks) for total of 15mos (see full labeling).
rucaparib Rubraca 200mg, 250mg, 300mg tabs Recurrent epithelial ovarian cancer: 600mg twice daily until disease progression or unacceptable toxicity
Topoisomerase inhibitor
topotecan Hycamtin 4mg pwd for IV infusion after reconsti
tution and dilution
1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle
Vascular Endothelial Growth Factor (VEGF) Inhibitor
bevacizumab Avastin 100mg, 400mg soln for IV infusion after dilution Recurrent ovarian cancer (platinum-resistant): 10mg/kg every 2wks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3wks with topotecan (every 3wks); (platinum-sensitive): 15mg/kg every 3wks with carboplatin/ paclitaxel for 6 cycles and up to 8 cycles or carboplatin/ gemcitabine for 6 cycles and up to 10 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent until disease progression. Stage III/IV ovarian cancer: 15mg/kg every 3wks with carboplatin/ paclitaxel for up to 6 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs first.
bevacizumab-awwb Mvasi 100mg, 400mg soln for IV infusion after dilution
bevacizumab-bvzr Zirabev 100mg, 400mg soln for IV infusion after dilution
bevacizumab-maly Alymsys 100mg, 400mg soln for IV infusion after dilution Recurrent epithelial ovarian cancer (platinum-resistant): 10mg/kg every 2wks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3wks with topotecan (every 3wks).
NOTES

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 11/2022)